Hyperparathyroidism in Biological Technology

Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia

... an important validation of our novel approach to treating secondary hyperparathyroidism in CKD patients." MTPC's President and Representative Director, Natsuki ... in countries worldwide. About Secondary Hyperparathyroidism Secondary hyperparathyroidism ("SHPT") is a condition commonly associated with chronic kidney disease ...

Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease

... these patients have vitamin D insufficiency, which can lead to secondary hyperparathyroidism and resultant debilitating bone diseases. There is growing evidence that ... portfolio of new therapies for Vitamin D insufficiency and secondary hyperparathyroidism associated with CKD. In addition, the Company is developing novel ...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

... require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are usually associated with secondary hyperparathyroidism (and its related cardiovascular complications), renal osteodystrophy and soft tissue mineralization. ESRD patients usually require treatment with ...

Cytochroma Closes $45 Million Series C Financing

... related to altered vitamin D metabolism in chronic kidney disease ("CKD") patients, and include CTA018 and CTAP201 for the treatment of secondary hyperparathyroidism ("SHPT"), and CTAP101 for the treatment of vitamin D insufficiency. These three lead products address significant markets that are expected to grow ...

Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.

... has acquired ROCALTROL(R) (calcitriol) from Roche Laboratories Inc. ROCALTROL is a vitamin D analog prescribed by nephrologists for the management of hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (CRF) and by endocrinologists for the management of ...

Cytochroma Appoints R. Richard Wieland II As CFO

... has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency. About Chronic Kidney Disease According to the National ...

Cytochroma opens U.S. headquarters in Illinois

... has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency. About Chronic Kidney Disease According to the National ...

Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO

... for vitamin D deficiency and secondary hyperparathyroidism in patients with moderate-to-severe CKD. ... hyperparathyroidism. If untreated, secondary hyperparathyroidism can cause debilitating bone diseases and ... and preventing vitamin D deficiency and secondary hyperparathyroidism in CKD patients, but Dr. Geoffrey A. Block, ...

Bone Care Names New Chairman

... commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney (renal) disease, osteoporosis and psoriasis. The ... Injection and Hectorol(R) Capsules for the treatment of secondary hyperparathyroidism in patients with end-stage renal ....

Americas Third Coast nurtures biotechnology

... ) specializes in novel vitamin D therapies for people with chronic kidney disease (CKD). The companys main drug, Hectorol, treats secondary hyperparathyroidism (SHPT) in patients with CKD. Healthy kidneys produce D hormone, which regulates calcium balance. Left untreated, low D hormone levels often ...

FDA approves Bone Cares Hectorol for treatment of kidney disease

... and strength for Hectorol (doxercalciferol) Capsules. Hectorol, a pro-hormone vitamin D2 analog, is currently approved for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the United States, and is now approved for the treatment of SHPT that develops in the earlier stages (stages three and ...

Massachusetts firm to buy UW spinoff Bone Care for $600 million

... chief motive for the merger was to bring Bone Care's flagship product, Hectorol, into its stable of renal disease drugs. Hectorol treats secondary hyperparathyroidism in patients with chronic kidney disease. While Genzyme's Renagel product has gained substantially in the market sales were up 19 percent in the ...

Bone Care expands patent protection of core drug offering

... that will extend protection of its core druc, Hectorol. The patent, which will expire in 2021, covers the company's hormone therapy treatment for hyperparathyroidism in chronic kidney disease patients, as well as the new version of Hectorol which Bone Care is currently working to complete. Bone Care uses ...

FTC has fast-tracked Bone Care merger

... Bone Cares current commercial and therapeutic focus is in nephrology, utilizing Hectorol, a novel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the company is ...

Genzyme acquistion of Bone Care approved, significant impact forecast

... was based around the research of Hector DeLuca - currently president and CEO of Deltanoid Pharmaceuticals - and is used to treat secondary hyperparathyroidism in patients on dialysis and early stages of chronic kidney disease. Hectorol will be added to Genzyme's renal line of products for treating ...

Genzyme sues former Bone Care employees

... BCI, a company that specialized in Vitamin D products, was best known for producing Hectorol, a Vitamin D drug used to treat secondary hyperparathyroidism in patients on dialysis and in the early stages of chronic kidney disease. As part of a merger, Genzyme purchased BCI last July for an estimated ...